25 September 2016

Virotec to raise £9m

08/07/05 Robert Tyerman

Environmental and extractive waste-treatment specialist Virotec International is raising £9.3 million at 30p and says it expects to report a maiden profit for the year to last month.

Queensland-based Virotec, headed by executive chairman Brian Sheeran, lost the equivalent of £6 million in 2003-04 (on revenues of £770,000 and after directors' fees of £3 million). More recently it has begun to turn the corner. In December, the AIM-quoted company says it expects to report pre-tax profits of between £1.35 million and £1.75 million for the year to June.

Last December, Virotec received £650,000 in cash and debt repayment from selling its oil refining technology business HydroDec to another company, Vert-eco. The deal also brought the company a 38 per cent stake in the purchaser's equity and it keeps a five per cent royalty on HydroDec's gross revenues.

Last month, Virotech won a contract to treat waste rock at Skytop Mountain in Pennsylvania, whose initial phase could be worth up to £700,000, says Sheeran. The company has now also clinched an exclusive agreement with Saudi Arabia's family-owned Al-Othman group, whereby Al-Othman will sell Virotec's environmental services throughout the desert kingdom (which has only lately become aware of alarming contamination levels from its oil industry).

Broker Numis is handling the placing for Virotec, whose shares were up 2p this morning to 33.75p. They could make further gains.

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

A gold medal ingredient 22/09/16

It’s hard work building a consumer brand, but Science in Sport is giving it a good go. The company has developed a range of sports nutrition products which have credibility from elite athlete users who won 34 medals at Rio.

A solid year at Brooks MacDonald 21/09/16

Fund manager Brooks MacDonald has recorded a solid year of asset growth. Funds under management grew by almost 12 per cent overall, which was a good result against a tricky market backdrop.

Styles & Wood upgraded on deal 21/09/16

Styles & Wood shares have doubled in value over the last six months as the strategy to diversify the customer base and focus on profits rather than revenue growth has gained momentum. A good set of interim results has just been followed by an earnings-enhancing acquisition.

Where's the beef? 15/09/16

Crawshaw Group shares have come crashing back to earth following a profit warning. When a highly rated growth stock hits an air pocket you run the risk of a big correction and the shares have fallen 40 per cent today.

Safestay hurt by downgrade 13/09/16

Hostel operator Safestay has released a slightly disappointing set of interim figures. Rather than becoming profitable this year there is now likely to be a small loss and the market has consequently cut back profit forecasts for the following years.

Back to basics at EKF 12/09/16

EKF Diagnostics interim results showed the benefit of refocusing on its core point-of-care (POC) diagnostics tests. Revenues were up 18 per cent, which was a welcome result after the disastrous foray into molecular diagnostics.

More News